MGO One Seven LLC Acquires 50,303 Shares of AbbVie Inc. $ABBV

MGO One Seven LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 187.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 77,093 shares of the company’s stock after acquiring an additional 50,303 shares during the quarter. MGO One Seven LLC’s holdings in AbbVie were worth $17,850,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Ellenbecker Investment Group grew its position in AbbVie by 0.8% in the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after acquiring an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA lifted its holdings in AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after buying an additional 45 shares during the period. Matthew Goff Investment Advisor LLC raised its holdings in AbbVie by 0.3% in the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after purchasing an additional 45 shares in the last quarter. Centennial Wealth Advisory LLC boosted its stake in AbbVie by 2.2% in the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock valued at $484,000 after acquiring an additional 45 shares in the last quarter. Finally, Willner & Heller LLC increased its position in AbbVie by 0.6% during the 3rd quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock valued at $1,759,000 after buying an additional 46 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of recent research reports. Berenberg Bank upgraded AbbVie from a “hold” rating to a “buy” rating and upped their target price for the company from $170.00 to $270.00 in a research report on Wednesday, September 17th. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Erste Group Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Morgan Stanley increased their price target on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $246.89.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Multiple clinical and pipeline updates point to ongoing product-cycle growth (Phase 1 ABBV‑243 safety data, progress on icalcaprant, and completed real‑world studies for Rinvoq and upadacitinib), supporting longer‑term revenue diversification away from Humira. ABBV‑243 Phase 1 Trial
• Positive Sentiment: Zacks and other analysts highlight immunology momentum — strong Skyrizi and Rinvoq demand is expected to help offset Humira LOE, which is a constructive revenue thesis for FY‑2025/2026. Zacks: Immunology expectations
• Positive Sentiment: Dividend-focused coverage (Seeking Alpha pieces) and a recent buy rating from Berenberg support income‑oriented and value investors who view ABBV’s payout and yield as a stabilizer. Seeking Alpha: Dividend thesis Berenberg buy
• Neutral Sentiment: Press swirl about potential suitors for Revolution Medicines (reports that Merck may be in talks) creates market noise that can influence sector comps and M&A speculation but does not change AbbVie’s fundamentals unless a deal is announced. FT: Merck talks on Revolution
• Negative Sentiment: AbbVie publicly denied reports it was in talks to acquire Revolution Medicines after earlier speculation drove gains in both names; the denial removed the takeover premium and likely triggered short‑term selling pressure. Barron’s: AbbVie denies talks
• Negative Sentiment: Management’s updated Q4 and FY‑2025 EPS guidance came in at the low end or slightly below consensus (Q4: 3.320–3.360 vs. cons. 3.360; FY: 10.610–10.650 vs. cons. 10.650), which can cap near‑term upside and weigh on sentiment. (Company guidance update)
• Negative Sentiment: AbbVie flagged IPR&D and related expenses that will negatively impact Q4 EPS, a known near‑term earnings headwind highlighted by Seeking Alpha coverage. Seeking Alpha: IPR&D Q4 EPS impact

AbbVie Stock Down 1.8%

Shares of NYSE:ABBV opened at $220.06 on Monday. The company has a market cap of $388.93 billion, a P/E ratio of 166.71, a PEG ratio of 0.92 and a beta of 0.36. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The company has a 50-day moving average price of $226.59 and a 200 day moving average price of $215.53.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is currently 496.97%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.